secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001439222-26-000018
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios outlines 2026 milestones: AQVESME launch in thalassemia, potential sNDA for sickle cell disease
--------------------------------------------------------------------------------

- AQVESME (mitapivat) U.S. approval in thalassemia Dec 2025; commercial launch underway, product available late Jan 2026.
- Pre-sNDA meeting with FDA for mitapivat in sickle cell disease expected Q1 2026; U.S. submission to follow.
- Pipeline: tebapivat Phase 2 sickle cell topline H2 2026; Phase 2b LR-MDS topline H1 2026.
- AG-236 (siRNA for PV) Phase 1 healthy volunteer topline H1 2026; AG-181 Phase 1b PKU trial init H1 2026.
- Target >$1B peak global sales from existing thalassemia and PK deficiency commercial presence.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000143922226000018/0001439222-26-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000143922226000018/agio-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001439222-26-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer